McKesson and CD&R close in on buyout of US infusion provider
Option Care Health is in advanced talks on a joint bid from McKesson and CD&R valuing it at more than $5 billion, including debt.
Option Care Health is in advanced talks on a joint bid from McKesson and CD&R valuing it at more than $5 billion, including debt.
New Capricor extension data support slower DMD arm decline, but H.C. Wainwright and Roth still see a complete response letter as more likely.
Merck’s tulisokibart met its Phase 2b HS goal and will move to Phase 3. H.C. Wainwright sees first anti-TL1A skin data as a class plus for Shattuck.
Eli Lilly CEO Dave Ricks says obesity-drug cash will fund slightly larger buys in sleep, cancer, brain disease, and other underserved science.
4D-150 is now in Phase 3 for DME after two-year SPECTRA data showed durable vision gains and fewer injections, expanding the race with implants like AXPAXLI.
Early lab results show Claude found a CRISPR-like repeat array tied to a reverse transcriptase. No proven editing tool yet.